App Approval Provides Flexibility for Patients Treated With Abbott’s Neuromodulation Devices

The Food and Drug Administration (FDA) has approved an iOS-compatible app designed to work in tandem with Abbott’s neuromodulation technologies. The Company hopes the app will eliminate the need for patients to carry a separate programmer device and improve remote care.

The Patient Controller app, which is part of Abbott’s NeuroSphere™ Digital Care connected care management platform, works with the Apple iPhone (X, XR, SE and Version 6 and up), as well as the Apple iPod (Generation 6 and 7). It is compatible with Abbott’s Infinity™ DBS System for patients with Parkinson disease or essential tremor, Proclaim™ XR SCS System for patients living with chronic pain, and Proclaim™ DRG Neurostimulation System for patients with chronic pain in the lower limbs caused by complex regional pain syndrome or causalgia.

“The approval of Abbott’s Patient Controller app with personalized access to therapy is a landmark event, as we are now able to provide patients a way to access personalized therapy from a compatible and secure iOS device so that people can live their lives and seamlessly manage conditions like chronic pain and movement disorders,” said Keith Boettiger, vice president, Neuromodulation, Abbott.

The app is expected to be available in the coming weeks.

For more information visit neuromodulation.abbott.